-
Eyenovia Inc (EYEN) provides update on Betaliq merger
-
Eyenovia Inc (EYEN) Provides Development Update on Optejet User Filled Device (UFD)
-
Eyenovia Inc (EYEN) Regains Nasdaq Compliance
-
Eyenovia Inc (EYEN) Announces Debt Restructuring Including Amendment to Senior Secured Debt
-
H.C. Wainwright Reiterates Neutral Rating on Eyenovia (EYEN)
-
Eyenovia Inc (EYEN) Announces 1:80 Reverse Share Split
-
Eyenovia (EYEN) Engages Chardan as Advisor for Review of Strategic Alternatives
-
Eyenovia Inc (EYEN) Halted, News Pending
-
Eyenovia Inc (EYEN) Prices 20.09M Share Offering at $0.0969
-
Eyenovia Inc (EYEN) Prices $1.3M Offering at $0.1076/sh
-
Eyenovia Inc (EYEN) Provides Update on Restructuring Efforts
-
H.C. Wainwright Downgrades Eyenovia (EYEN) to Neutral
-
Brookline Capital Markets Downgrades Eyenovia (EYEN) to Hold
-
Eyenovia Inc (EYEN) Provides Update on Phase 3 CHAPERONE Study
-
Eyenovia Inc (EYEN) Tops Q3 EPS by 2c
-
Eyenovia Inc (EYEN) Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet
-
Eyenovia Inc (EYEN) Files $100M Mixed Shelf
-
Eyenovia Inc (EYEN) Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
-
Eyenovia Inc (EYEN) Prices 8.7M Share Offering at $0.46/sh
-
Eyenovia (EYEN) Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
-
Eyenovia Inc (EYEN) Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer
-
Eyenovia (EYEN) Announces Pricing of $5.14 Million Public Offering
-
Eyenovia Inc (EYEN) Announces Proposed Public Offering
-
H.C. Wainwright Reiterates Buy Rating on Eyenovia (EYEN)
-
Eyenovia Inc (EYEN) Misses Q2 EPS by 6c
-
Eyenovia Inc (EYEN) & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
-
Eyenovia Inc (EYEN) and Senju Pharmaceutical Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
-
NovaBay Pharma (NBY) and Eyenovia (EYEN) Commence Co-Promotion Activities
-
Eyenovia Inc (EYEN) Prices 7.56M Share Offering at $0.66/sh

